BHVN Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which i…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today? Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%... | ||
 Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced? Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its... | ||
 Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’ | ||
 Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation Warby Parker's 1,500-contract December $22.50 call trade, tied to a stock purchase, signals an institutional covered call. The setup looks bullish on growth and earnings, but a rich valuation, slowing customer growth, and rising capex limit the stock's potential upside. | ||
 Biohaven’s epilepsy drug hit with FDA clinical hold Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans. | ||
 Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. | ||
 Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit. | ||
 Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials Biohaven Ltd. (NYSE:BHVN) shares fell 17% on Thursday morning after the company paused new patient enrolment in clinical trials of BHV-7000 following a partial clinical hold from the U. | ||
 BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite. | ||
 FDA places partial hold on Biohaven’s epilepsy drug Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval. | ||
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says Biohaven (BHVN) is facing a quieter stretch for major drug catalysts, and limited patient data and r | ||
 Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1. 9% to $15. | ||
 Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven’s lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven’s Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines […] | ||
 Why Biohaven Stock Was Rocking the Market This Week It signed a collaboration and licensing deal potentially worth $795 million. | ||
 Slate Medicines Starts Migraine Treatment Study By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge. | ||
 SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout. | ||
 BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim. | ||
Sector Update: Healthcare Stocks Decline Late Afternoon Healthcare stocks fell late Wednesday afternoon, with the NYSE Healthcare Index shedding 1% and the | ||
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim. | ||
 Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal Biohaven Ltd. (NYSE:BHVN) shares gained 7% on Wednesday after the biotechnology company announced a strategic global licensing agreement with SK Biopharmaceuticals covering its Kv7 ion channel platform and epilepsy candidate opakalim. | ||
 Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction. | ||
 Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has already repriced Regeneron Pharmaceuticals positively. The key issue for... | ||
 Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […] | ||
Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged | ||